FOXO4-DRI

FOXO4-DRI is a lab-made peptide studied as a senolytic — a compound meant to clear out senescent cells.

Disrupts the FOXO4-p53 interaction so p53 can trigger apoptosis in senescent cells. [Source: Peptide Dosing Protocols]

FOXO4-DRI is a lab-made peptide designed as a senolytic agent, which means it aims to eliminate senescent cells—cells that have stopped dividing but do not undergo apoptosis, leading to potential inflammatory effects on surrounding tissues. The mechanism of action involves disrupting the interaction between FOXO4 and p53, a crucial protein that regulates the cell cycle and apoptosis. By inhibiting this interaction, FOXO4-DRI allows p53 to trigger apoptosis in senescent cells, thereby promoting their clearance from the body.

The evidence supporting the efficacy of FOXO4-DRI primarily comes from mouse and cell studies, with no human trials reported as of June 2026. In a foundational study by Baar et al. (2017) published in Cell, aged and chemotherapy-treated mice were administered FOXO4-DRI at a dosage of 5 mg/kg via intraperitoneal injection on an intermittent schedule. The results indicated improvements in health markers, including restored coat density and enhanced physical activity, suggesting that FOXO4-DRI effectively targets senescent cells in vivo.

The peptide is constructed using D-retro-inverso (DRI) technology, which involves creating a peptide from mirror-image amino acids arranged in reverse order. This design enhances the peptide's stability, making it more resistant to degradation in the body compared to standard peptides. The reconstitution of a 10 mg vial of FOXO4-DRI with 3.0 mL of BAC water yields a concentration of approximately 3.33 mg/mL, facilitating dosing calculations for potential users. However, it is crucial to note that the dosing regimens reported in the community are not validated by clinical trials and should be approached with caution.

Overall, while FOXO4-DRI shows promise in preclinical studies for its ability to clear senescent cells, the lack of human clinical data necessitates careful consideration and further research to establish its safety and efficacy in humans. [Source: Peptide Dosing Protocols]

Provider notes: [PDP compound] foxo4-dri